PMID- 12764679
OWN - NLM
STAT- MEDLINE
DCOM- 20031212
LR  - 20181113
IS  - 1432-9417 (Print)
IS  - 1432-9417 (Linking)
VI  - 7
IP  - 3
DP  - 2003 May
TI  - [Evaluation of her-2/neu amplification/overexpression in OSCC with fluorescence 
      in situ hybridization (FISH) and immunohistochemistry].
PG  - 138-45
AB  - INTRODUCTION: The human epidermal growth factor receptor ( her-2/ neu) 
      protooncogene encodes a membrane tyrosine kinase with homology to the epidermal 
      growth factor receptor (EGFR). Amplification and protein overexpression have been 
      identified in various solid tumors and a significant association with poor 
      clinical outcome was reported. This investigation was performed to assess the 
      frequency of her-2/ neu overexpression and to compare these results with clinical 
      outcome in OSCC. MATERIAL AND METHODS: Archival biopsy specimens from 97 
      untreated OSCCs were evaluated using a polyclonal antibody A0485 (Dako). Only 
      membrane staining intensity and pattern were evaluated according to the 
      guidelines of the clinical trial assay recommendations (0-3+) for breast 
      carcinoma. Score 0 and 1+ were interpreted as negative for HER-2/NEU protein 
      overexpression and 2+ and 3+ as positive. FISH analysis with directly labeled 
      probes for her-2/ neu and chromosome 17 was performed on the same specimens. The 
      ratio between her-2/ neu and chromosome 17 signals was calculated after selection 
      of 20-40 non-overlapping tumor cells. The tumor was considered amplified if the 
      ratio was above 2. RESULTS: In 11 out of 97 biopsies (11.3%) membranous 
      overexpression (score 2+ and 3+) of her-2/ neu was shown by immunohistochemistry. 
      FISH analysis in 42 cases revealed amplification in 14 cases. Concordance between 
      immunohistochemistry and FISH was found in 86%. Clinical-pathological data as 
      well as survival revealed no correlation with her-2/ neu status. DISCUSSION: In 
      spite of missing correlation between survival and her-2/ neu overexpression in 
      our study, the predictive value of the her-2/ neu protooncogene in adjuvant 
      therapy in OSCC needs further investigation.
FAU - Scheer, M
AU  - Scheer M
AD  - Klinik und Poliklinik fur Mund-, Kiefer- und Plastische Gesichtschirurgie, 
      Universitat zu Koln, Joseph-Stelzmann-Strasse 9, 50935, Koln, 
      m.scheer@uni-koeln.de
FAU - Prange, W
AU  - Prange W
FAU - Petmecky, K
AU  - Petmecky K
FAU - Schirmacher, P
AU  - Schirmacher P
FAU - Zoller, J E
AU  - Zoller JE
FAU - Kubler, A C
AU  - Kubler AC
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Uberexpression/Amplifikation des her-2/neu-Protoonkogens in oralen 
      Plattenepithelkarzinomen.
DEP - 20030307
PL  - Germany
TA  - Mund Kiefer Gesichtschir
JT  - Mund-, Kiefer- und Gesichtschirurgie : MKG
JID - 9716576
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biopsy
MH  - Carcinoma, Squamous Cell/*genetics/mortality/pathology
MH  - Chromosomes, Human, Pair 17
MH  - Female
MH  - Gene Amplification/*genetics
MH  - Gene Expression Regulation, Neoplastic/physiology
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Mouth Mucosa/pathology
MH  - Mouth Neoplasms/*genetics/mortality/pathology
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Receptor, ErbB-2/*genetics
MH  - Survival Analysis
EDAT- 2003/05/24 05:00
MHDA- 2003/12/13 05:00
CRDT- 2003/05/24 05:00
PHST- 2003/05/24 05:00 [pubmed]
PHST- 2003/12/13 05:00 [medline]
PHST- 2003/05/24 05:00 [entrez]
AID - 10.1007/s10006-003-0460-5 [doi]
PST - ppublish
SO  - Mund Kiefer Gesichtschir. 2003 May;7(3):138-45. doi: 10.1007/s10006-003-0460-5. 
      Epub 2003 Mar 7.